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470Techniques to harvest diseased human peripheral
arteries and measure endothelial function in an
ex vivo model
Ryan O. Lakin, MD,a Weifei Zhu, PhD,b Lindsay Feiten, BS,b and Vikram S. Kashyap, MD,a Cleveland, Ohio
Objective: Endothelial dysfunction has been studied in animal models. However, direct evidence of endothelial function
from human vessels is limited. Our objectives were to optimize methods in harvesting human arteries from amputation
specimens, determine endothelial function, and measure responsiveness to L-arginine, a nitric oxide precursor.
Methods: Fresh amputation specimens were transferred expeditiously from the operating room to the bench laboratory for
dissection and arterial harvest in an Investigational Review Board-approved protocol. Popliteal and tibial vessels were
examined in pilot experiments leading to the use of the anterior tibial artery in consecutive experiments. Human lower
extremity anterior tibial artery segments were harvested from 14 amputation specimens. Specimens were rapidly collected
and divided for endothelial-dependent relaxation (EDR) studies in a tissue bath apparatus, immunohistochemistry, and
intravascular ultrasound-derived virtual histology. A total of 47 ring segments were studied. The data were compared
with two-way analysis of variance.
Results:Human lower extremity arteries exhibited low responsiveness to acetylcholine (EDR, 24.9%; acetylcholine, 10L4).
L-arginine supplementation enhanced EDR by 38.5% (P < .0001). N-nitro-L-arginine methyl ester abrogated EDR (P <
.0001) in vessels exposed to L-arginine. Arterial responsiveness was intact in all vessels (endothelial independent relax-
ation to sodium nitroprusside, 113.2% ± 28.1%). Histology and immunohistochemistry conﬁrmed intact endothelium by
morphometric analysis, cluster of differentiation 31, endothelial nitric oxide synthase, and arginase II staining.
Intravascular ultrasound-derived virtual histology indicated atheroma burden was 11.9 ± 4.7 mm3/cm, and plaque
stratiﬁcation indicated ﬁbrous morphology was predominant (59.9%; necrotic core, 16.9%; calcium, 11.2%). Variations in
plaque morphology did not correlate with endothelial function or responsiveness to L-arginine.
Conclusions: Human lower extremity arteries demonstrate low baseline endothelial function in patients requiring
amputation. Endothelial dysfunction is improved by L-arginine supplementation in an ex vivo model. These results
support strategies to increase local levels of nitric oxide in human vessels. (J Vasc Surg 2013;58:470-7.)
Clinical Relevance: Endothelial dysfunction is thought to be the precursor to atherogenesis. Although endothelial
function has been studied extensively in animal models and in human coronary vessels, direct evidence for endothelial
function in the peripheral arteries of patients with peripheral arterial disease is limited. This study shows direct evidence of
endothelial dysfunction in arteries harvested from amputation specimens. In addition, the dysfunction can be improved
with local addition of L-arginine. The ex vivo model described offers a ﬂexible assay to study pharmaceutical and biologic
agents in human arteries before expensive and time-consuming clinical trials.The seminal observation that endothelium is a key medi-
ator of vascular vasomotor reactivity was made in 1980 by
Furchgott and Zawadzki.1 The ability of the artery to relax
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://dx.doi.org/10.1016/j.jvs.2012.10.123derived relaxing factor, which was identiﬁed as nitric oxide
(NO) by Ignarro et al2 and Palmer et al.3 NO is thought to
play a pivotal role in the regulation of endothelial function
and to serve a cardioprotective role via its antithrombotic,
anti-inﬂammatory, and antiatherosclerotic properties. Con-
sistent with this construct, endothelial dysfunction is believed
to represent the earliest abnormality in the development of
atherosclerosis.4
Endothelial dysfunction studies in animal models have
been attributed to decreased NO production by endo-
thelial NO synthase (eNOS). Vasorelaxation can occur
through two mechanisms: endothelial-dependent vasore-
laxation (EDR) and endothelial-independent vasorelaxa-
tion (EIR). Through interaction with endothelial cell
surface receptors, mediators of EDR (acetylcholine [Ach],
bradykinin, etc) cause NO release. NO then diffuses to
the underlying smooth muscle cells and induces vasorelax-
ation. This process can be quantitatively assessed in the
laboratory, and the measurement of EDR of an artery
reﬂects endothelial function. Isolated vessel ring studies
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secondary to NO.1 This method has been used reliably in
previous animal models.5 Agonists for EDR (Ach, bradyki-
nin, calcium ionophore, etc) or EIR (sodium nitroprusside,
nitroglycerin, etc) can be used to determine the level of
endothelial and smooth muscle cell function. Furthermore,
antagonists, such as N-monomethyl L-arginine (L-NMMA)
and N-nitro-L-arginine methyl ester (L-NAME) can be
used as artiﬁcial inhibitors of eNOS and allow speciﬁc
controls for experimental ﬁndings and constructing of
dose-response curves.
The direct assessment of endothelial function in
patients affected by peripheral arterial disease (PAD) has
been scant. Targeted therapies to alleviate endothelial
dysfunction may signiﬁcantly impact long-term clinical
outcomes in patients with PAD. Thus, we proceeded to
investigate the feasibility of measuring endothelial function
in human lower extremity arteries harvested after amputa-
tion. Our objectives were to optimize methods in harvest-
ing human arteries from amputation specimens, determine
endothelial function using a tissue bath apparatus, and
measure responsiveness to L-arginine, a NO precursor.
We also sought to determine the feasibility of using intra-
vascular ultrasound (IVUS) imaging and immunohisto-
chemistry staining in this ex vivo model, and determine
any correlation to EDR measurement. These direct
measurements may lead to insights into biologic therapies
for PAD that target the endothelium.METHODS
This protocol was approved by the Cleveland Clinic
Institutional Review Board as a consent-exempt protocol
with evaluation of discarded pathological tissue only.
Patient-level information, clinical and demographic vari-
ables could not be obtained under these conditions.
Human lower extremity arterial segments were ob-
tained from amputation specimens. Our pilot experiments
of seven limbs (3 popliteal, 4 tibial) led to the following
methodologic observations.
1. Initially, we attempted to harvest arteries from both
above-knee and below-knee amputation specimens.
Below-knee amputation specimens yielded very little
usable arterial tissue for investigation. Thus, above-
knee specimens were used uniformly leading to the
data in this study.
2. A single above-knee amputation specimen may have
a combination of patent tibial, popliteal, and femoral
arteries for examination. Because we sought to keep
the time elapsed from amputation to endothelial
function measurement at a minimum, harvesting
the entire patent arterial tree was too time-
consuming. All studies were undertaken immediately
upon vessel procurement, minimizing any delay or
endothelial deterioration.
3. We used a tissue bath chamber that was w10 mL in
size. The popliteal artery averaged 5 to 7 mm indiameter. Smaller-diameter popliteal arteries were
used but most were too large to mount in our system.
4. The anterior tibial artery was 2 to 3 mm in diameter
and, if patent, became the preferential artery to
study. Eight to 10 cm of this artery could be
dissected quickly, and patent segments were identi-
ﬁed and mounted with minimal delay. Despite exten-
sive plaque burden and calciﬁcation in most vessel
segments, the small tungsten wires allowed for
precise ﬁtting into the lumen.
Human lower extremity artery segments (anterior tibial
artery, 80%; popliteal artery, 20%) were harvested from 14
patients undergoing lower extremity amputation. Speci-
mens were rapidly collected and divided for EDR studies
in a tissue chamber, immunohistochemistry, and IVUS-
derived virtual histology (IVUS-VH). Adjacent vessel
segments were used for EDR, IVUS, and immunohisto-
chemistry for ideal correlation. A total of 47 ring segments
were studied.
Statistical analysis. Data were compared with two-way
analysis of variance. Statistical signiﬁcance was set at P< .05.
Statistical analysis was performed using Prism software
(GraphPad, San Diego, Calif). Results are expressed as
mean6 standard error of the mean. No other laboratory or
demographic data were obtained for our specimens. Our
Investigational Review Board approval for this preclinical
study allowed us access to discarded tissue from human
lower extremity amputations, but not for a full chart review.
Accordingly, we were unable to account for clinical severity
of disease, operative indications, or presence of infection.
Studies of endothelial and smooth muscle cell
function. The harvested arteries were sectioned into 4-mm
segments and mounted on standard tungsten wire trian-
gles (A-M Systems, Everett, Wash), attached to isometric
force displacement transducers (Radnoti 159920, Monro-
via, Calif), and placed into tissue baths.6 The Radnoti
apparatus could accommodate four simultaneous studies,
thus we took three or four segments from each vessel for
a total of 47 rings for this experiment. The tissue baths
were temperature controlled via a heated water jacket at
37C. Standard Krebs-Henseleit solution (NaCl 118mM,
NaHCO3 25mM, glucose 5.6mM, KH2PO4 1.2mM,
KCL 4.7mM, MgSO4 1.2mM, CaCl2 1.5mM) was used
with a 95% oxygen and 5% carbon dioxide gas mixture
bubbled into the baths.
Preload (2 g) was applied to the arterial rings, and the
vessels were allowed to equilibrate for 1 hour using a stan-
dardized protocol adapted from previous animal studies
(Fig 1).7-9 The arteries were then constricted using
a high potassium solution (standard Krebs except KCl
122mM) to measure maximal contractile force for the
artery (F-max). The baths were then emptied, rinsed three
times with the Krebs solution, and again allowed to equil-
ibrate. At this point, the arteries were constricted to 75% of
F-max with 105 M norepinephrine (NE; Sigma, St. Louis,
Mo). Ach (Ach; Sigma) was then added in incremental log
doses to achieve 107 to 104 M bath concentrations for
Fig 1. The endothelial-dependent relaxation (EDR) curve was
established using incremental doses of acetylcholine (Ach). NE,
Norepinephrine.
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addition of L-arginine (1 mL of 1M solution; Sigma). EIR
was measured in a similar fashion using sodium nitroprus-
side (NTP; Sigma) in the seven pilot vessels. Baths were
rinsed and arterial segments brought to 75% F-max with
NE between each reagent. Vessels were subjected
to eNOS blockade by incubating the vessel segments
(n ¼ 6) in L-NAME (1 mL of 100mM; Sigma) for 1
hour during the equilibration period.
Immunohistochemical analysis. Intact endothelial
presence and morphology were evaluated in a select
number of specimens.
Arginase-1 and arginase-2. Immunohistochemistry
for arginase-1 (1:200 dilution) and arginase-2 (1:100
dilution) was performed using polyclonal rabbit antihuman
antibodies. Tissue sections were subjected to heat-induced
epitope retrieval pretreatment for 3 minutes at 95C in
0.01M citrate buffer (pH 6.0), allowed to cool, immersed
in 1% hydrogen peroxide/methanol before blocking with
5% skim milk, and incubated with primary antibody for 1
hour at room temperature. Slides were then developed
for 5 minutes with 3-30-diaminobenzidine chromogen,
counter-stained with hematoxylin, and coverslipped.
eNOS and cluster of differentiation 31. Slides were
treated with 5% normal goat serum in phosphate-buffered
saline (PBS) for 30 minutes at room temperature. The
slides were incubated for 30 minutes with a 1:100 dilution
of primary anti-eNOS rabbit antibody. After three washes
with PBS, the sections were incubated with biotinylated
secondary antibody, and incubated with peroxidase sub-
strate. Antibody-labeled specimens were rinsed with dis-
tilled water for 5 min, dehydrated, and mounted.
The endothelial marker cluster of differentiation (CD)
31 was also visualized by immunoreactive staining. Sections
were ﬁxed in acetone for 10 minutes and rinsed with PBS.
The slides were incubated with 10% normal goat serum for
10 minutes and then with primary mouse antihuman anti-
bodies against CD31 for 60 minutes. The slides were
washed with PBS and incubated with biotinylated sec-
ondary antibody along with peroxidase substrate. Antibody-
labeled specimens were rinsed with distilled water for 5
minutes, dehydrated, and mounted.Detection of plaque constituents by IVUS-VH.
The harvested arteries (n ¼ 9) were mounted in positions
approximating their orientation in situ. The vessel was
cannulated, secured with steel pins, and perfused with
PBS solution at 100 mm Hg. This technique was used
to simulate in vivo conditions.10,11 An initial pullback
was performed to qualitatively ascertain plaque composi-
tion and morphology. An IVUS catheter (Eagle Eye Gold
Catheter; Volcano Corp, San Diego, Calif) was inserted
into the vessel as far distally as possible and the catheter
was pulled back (Trak Back II; Volcano Corp) until
a region of plaque was clearly visible on the IVUS monitor
(s5 Imaging System; Volcano Corp). At this location,
a suture marker was attached to the vessel surface and
clamped with a forceps visible in the IVUS image as
a highly echoic streak. The IVUS screen was frozen and
the image captured to videotape. This procedure was
repeated as the catheter advanced toward the proximal
end of the vessel for up to 10 markers.
Owing to the ﬂexibility of this vessel-testing apparatus,
the geometric, compositional, and mechanical data were
obtained from the vessel. The luminal border was identiﬁed
by visualization in the laboratory during postimaging anal-
ysis. Once this border was determined, several measure-
ments were derived:
1. Lumen cross-sectional area (CSA), the area bounded
by the luminal border;
2. Calciﬁc deposits, which appear as bright echoes that
obstruct the penetrance of the ultrasound;
3. Fibrous plaques, which have an intermediate echoge-
nicity; and
4. Necrotic core zones, which have reduced echo-
genicity.12
Areas comprising calcium, collagen ﬁbers, and necrotic
core were identiﬁed on the corresponding IVUS-VH. VH
was performed using a modiﬁed coronary artery algorithm
classiﬁed by color indicating calcium (white), necrosis
(red), and ﬁbrous (green) plaque components (Fig 2).
RESULTS
Endothelial function of diseased human arteries was
assessed using a tissue chamber with endothelial-
dependent and endothelial-independent agonists. EDR is
expressed as a percentage secondary to Ach-induced vaso-
relaxation. Human lower extremity arteries exhibited low
EDR. EDR was 0.5% 6 13.3% at 107, 13.9% 6 34.6%
at 106, and 17.9% 6 34.8 at 105. Even at the highest
molar dose of Ach of 104, EDR was only 24.9% 6
38.8%. Pilot study popliteal segments (n ¼ 11 rings)
were included in baseline EDR/EIR calculations and
were not statistical outliers.
Endothelial dysfunction was ameliorated by L-arginine
supplementation in this ex vivo model (n ¼ 18 rings).
L-arginine supplementation enhanced EDR by 38.5%
(P < .0001; Fig 3). EDR was 26.6% 6 29.2 at 107,
50.9% 6 26 at 106, 60.3% 6 27.6% at 105, and
Fig 2. Intravascular ultrasound is able to predict the composition of plaques without any a priori information on the
histology of the vessel. A, An anterior tibial artery is seen in this gray-scale intravascular ultrasound image. B, A virtual
histology image is created using a modiﬁed coronary artery algorithm classiﬁed by color indicating calcium (white),
necrosis (red), and ﬁbrous (green) plaque morphology.
Fig 3. Effect of L-arginine supplementation is shown on human
lower extremity arteries. Endothelial-dependent relaxation (EDR)
is augmented in the L-arginine group (P < .0001) by two-way
analysis of variance. N-nitro-L-arginine methyl ester (L-NAME)
blocked acetylcholine (Ach)-induced EDR (P < .0001). Values are
shown 6 standard error of the mean. *P < .05, **P < .01 with
Bonferroni post-test comparisons for L-arginine vs L-NAME
groups.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 2 Lakin et al 47363.4% 6 27.1% at 104. The maximum relaxation more
than doubled with L-arginine supplementation. L-NAME
abrogated EDR (P < .0001) in vessels exposed to L-argi-
nine. EDR was –4.3% 6 10.6% at 107, –7.9% 6 18.4%
at 106, –11.4% 6 24% at 105, and –15.4% 6 31.5% at
104. This indicated that the relaxation exhibited in the
assay was secondary to the L-arginine/eNOS mechanism
with production of NO. Arterial responsiveness (EIR)
was intact in all vessels tested (n ¼ 7) with relaxation to
sodium nitroprusside at 113.2% 6 28.1%, indicating intact
smooth muscle response to a NO donor.
Histologic analysis conﬁrmed that diseased lower
extremity arteries had intact endothelium in the segments
adjacent to EDR evaluation. Immunohistology conﬁrmedintact endothelium by morphometric analysis, CD31,
eNOS, and arginase II staining (n ¼ 4 vessels; Fig 4).
IVUS-VH was used to characterize plaque burden.
Nine vessels were subjected to IVUS-VH. Plaque CSA
was 11.9 6 4.7 mm3/cm of vessel. Multiplying the plaque
CSA by the vessel length revealed an average total plaque
volume of 1288.9 mm3/vessel. Plaque stratiﬁcation indi-
cated ﬁbrous morphology was the predominant type
(59.9%). Arteries also had necrotic core (16.9%) and
calcium (11.2%) elements in the plaque. Average vessel
CSA was 22.0 mm2, and average lumen CSA was 10.1
mm2, representing an average vessel lumen occlusion of
54.3%. EDR response of individual vessels did not correlate
with plaque burden in our studies. Scatter plot analysis
(Fig 5) showed poor correlation of EDR to total plaque
volume, plaque CSA, average percentage occlusion,
average percentage necrotic core, and EIR.
DISCUSSION
This is the ﬁrst study that we know of using harvested
lower extremity arteries for assessing endothelial function.
The results of our studies of endothelial function are
both novel and compelling.
Previous studies have examined arteries in preclinical
models or from explanted normal arteries unaffected by
atherosclerosis. We examined EDR in diseased arteries har-
vested from amputated limbs presumably for severe athero-
sclerosis, gangrene, or pedal sepsis. EDR was improved
with the addition of L-arginine. Furthermore, we were
able to show that the addition of L-NAME, an inhibitor
of eNOS, abrogated EDR and established a speciﬁc control
for this experiment. The vessels retained the ability to vaso-
dilate with the NO donor sodium nitroprusside, which
indicated normal smooth muscle cell responsiveness to
NO. The ex vivo assessment of plaque burden and vessel
Fig 4. Immunohistochemistry staining of (A) cluster of differentiation (CD) 31, (B) endothelial nitric oxide synthase
(eNOS), and (C) arginase II demonstrates intact arterial endothelium (original magniﬁcation, 10).
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imaging of human lower extremity arteies.13 We had
hypothesized that increasing necrotic plaque would lead
to decreased EDR, which was not found in this limited
sample. The ex vivo model described offers a ﬂexible assay
to study pharmaceutical and biologic agents that may
improve endothelial function in diseased human vessels.
This platform could be used for other novel agents before
embarking on costly clinical trials.
In humans, measurement of endothelial function has
been mostly done with quantiﬁcation via angiography
in the coronary circulation. Endothelial dysfunction is
thought to be an early shift in balance in the vessel wall
that makes it vulnerable to vasospasm, thrombosis, and
lesion formation. Endothelial dysfunction also appears to
be a characteristic feature of patients with coronary artery
disease. Several groups have shown that epicardial coro-
nary arteries in patients with coronary artery disease
constrict at sites of angiographically demonstrated ob-
structive atherosclerotic disease and also at sites of plaque
formation in response to Ach.14-17 The same dose of Ach
causes vasodilation in coronary arteries of patients without
demonstrable evidence of coronary artery disease. In
contrast, the responses to nitroglycerin (a NO donor)
are similar in individuals with and without coronary artery
disease, indicating intact smooth muscle responsiveness to
NO, at least in mildly atherosclerotic coronary arteries.
Individuals with normal-appearing coronary angiogramsand risk factors (hypercholesterolemia, male sex, ad-
vancing age, smoking, diabetes mellitus, and family history
of coronary artery disease) for atherosclerosis also manifest
a vasoconstrictor response of the epicardial coronary
arteries in response to Ach.18,19 These observations
suggest that endothelial dysfunction, mediated by dimin-
ished NO production by epicardial coronary arteries,
precedes the development of angiographically demon-
strable atherosclerotic disease.
Previous attempts at understanding endothelial func-
tion using noninvasive methods have relied on measures
of brachial artery reactivity. This approach relies on the
evaluation of ﬂow-mediated vasodilation, which partly
represents endothelium-dependent function. The brachial
artery is occluded for 5 minutes using a blood pressure
cuff inﬂated to suprasystolic levels, followed by deﬂation
and measurement of brachial artery dilation by spectral
Doppler ultrasound imaging. Increases in arm blood ﬂow
are related to resistance vessel dilation (ie, reactive hyper-
emia). Because the increase in ﬂow and shear stress stimu-
lates the release of NO, brachial artery diameter changes
are believed to be secondary to NO release. This technique
is attractive because it is noninvasive and allows repeated
measurement. Despite its widespread use, there are both
technical and interpretive limitations.20 Some of the
changes in brachial artery diameter may be more related
to the performance of reactive hyperemia and outﬂow vaso-
dilation and resistance than brachial artery vasomotor
Fig 5. Scatter plot analysis displays correlation of endothelial-dependent relaxation (EDR) to total plaque volume,
percentage of plaque cross-sectional area (PCSA), average percentage occlusion (Occ), average percentage necrotic core
(NC), andendothelial-independent relaxation (EIR).R,R2, andP values are shown for eachplot.CSA,Cross-sectional area.
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is affected by atherosclerosis and may not be a relevant
indicator of lower extremity endothelial function.Our results showed low EDR in response to Ach
compared with similar studies in animal models and human
studies. An analysis of data collected by Padilla et al21
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dependent and endothelium-independent relaxation be-
tween pigs that exercise-trained for 16 to 20 weeks and
pigs that remained sedentary. No differences in vasomotor
function were found between the two groups, and their
artery segments showed an EDR response ofw80% to 90%
to equivalent doses of bradykinin. Woodman et al22 used
vascular ring studies to test their hypothesis that exercise
training preserves EDR in brachial arteries from hyperlipi-
demic pigs. Pigs grouped by normal-fat diet and high-fat
diet were subjected to exercise or sedentary training sched-
ules. Ach-induced relaxation was greatest in the normal-fat
exercise group at 83.5%, with poor relaxation of 50.5%
seen in the high-fat sedentary group.
Similarly, Hutchison et al23 tested aorta ring segments
from rabbits exposed to high-cholesterol diets and second-
hand smoke (SHS). The control group exhibited maximum
EDR of w90% in response to Ach. Hypercholesterolemia
impaired maximal Ach-induced relaxation. SHS further
impaired maximal Ach-induced relaxation to w40%. No-
tably, chronic dietary L-arginine improved endothelium-
dependent relaxation and reduced the SHS-associated
impairment of relaxation, reduced the effect of SHS to
accelerate intimal lesion formation, and tended to reduce
atherogenesis overall.
Patients scheduled for elective bypass surgery were
randomized by Hambrecht et al24 into a training or an inac-
tive control group. In vivo and ex vivo assessment of endo-
thelial function was performed in the left internal mammary
artery (LIMA). After 4 weeks of exercise training, the mean
vasodilatory response to themaximum concentration of Ach
was signiﬁcantly increased by 116%, whereas no signiﬁcant
change was detectable in patients of the control group.
Ex vivo ring studies showed EDR was preserved at >50%
relaxation in human LIMA, with similar concentrations of
Ach in organ tissue chambers. Similar results were reported
again in 2006.25 In patients with coronary artery disease,
EDR of mammary arteries was signiﬁcantly impaired in
those positive for the T-786C or the G894T eNOS poly-
morphism. The maximal vasodilatory response to Ach was
47% in patients with the T-786C polymorphism and 60%
in patients positive for the G894T polymorphism. LIMA
rings from wild-type variants responded to Ach with a 90%
ring relaxation. The Endothelial Protection, AT1 blockade
and Cholesterol-Dependent Oxidative Stress trial26 studied
the protective effects of angiotensin II type 1 receptor
blockade and statin use on human coronary LIMA in
patients undergoing coronary artery bypass grafting.
Maximal dilation in response to Ach 106M was 51% for
the control group, 69% for the statin-only group, 79% for
the angiotensin II type 1 receptor blocker group, and 86%
for the dual-therapy group. Taken together, these studies
have demonstrated retained endothelial function in normal
and disease states and highlight the potential for treatment
of endothelial dysfunction through various pharmacologic
modalities.
This work has several limitations. Given the constraints
of the IRB-approved protocol, no patient-level data couldbe obtained that might have affected endothelial function.
Thus, relevant variables of severity of ischemia, preoperative
gangrene, and patient clinical and demographic informa-
tion could not be collected and correlated to the arterial
results. The specimens obtained were limited to electively
planned lower amputation specimens from a single institu-
tion, and the results are based on a small number of har-
vested arteries. The time required between amputation,
vessel harvest, and tissue chamber analysis was kept at
a minimum but could have led to vessel wall deterioration.
Of note, “normal” arteries for comparison would be
ideal but challenging to obtain. Amputations performed
on trauma or cancer victims could provide additional data
in “normal” arteries from younger, healthier patients. In
general, there are very few amputations for oncologic or
trauma indications at our institution. Comparing leg arteries
with normal arteries trimmed from kidney or liver trans-
plants was considered, but this idea was discarded because
of the very different structure of the vessels in different arte-
rial beds. In addition, any leg specimens with oncologic
pathology were not released in a timely fashion to allow
endothelial function measurement. Correlating patient-
level clinical factors with limb-based endothelial function
and other parameters is the subject of future studies.
Factors other than L-arginine availability may be playing
a role in endothelial dysfunction, and the ex vivo results
presented heremay not completely reﬂect in vivo physiology.
Further ex vivo and in vivo studies are being planned to
determine the effects of L-arginine supplementation and
arginase blockade on lower extremity endothelial function.
The effects of plaque burden, thrombus, and arginase II
levels will be elucidated with additional arterial samples.
The role of NO modulators in PAD as clinical adjuncts
remains largely unknown. The ex vivo model described
offers a ﬂexible assay to study pharmaceutical and biologic
agents that may improve endothelial function in diseased
human vessels. We hope this platform will serve as a spring-
board to human clinical studies for patients with both acute
and chronic limb ischemia.
CONCLUSIONS
The methods used in our study demonstrate an ex vivo
model for IVUS-VH to establish plaque burden and
composition, and to test EDR in an organ chamber appa-
ratus of human arteries harvested from legs after amputa-
tion. Human lower extremity arteries demonstrate low
baseline endothelial function in patients requiring amputa-
tion. Endothelial dysfunction is improved by L-arginine
supplementation in an ex vivo model. These results support
clinical strategies to increase local NO levels in atheroscle-
rotic human vessels.
We thank the Lerner Research Institute Imaging Core
(J. Drazba) for help with automated immunohistochemistry.
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